Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
203
-
Total 13F shares, excl. options
-
154M
-
Shares change
-
+2.56M
-
Total reported value, excl. options
-
$3.69B
-
Value change
-
+$66.5M
-
Put/Call ratio
-
0.26
-
Number of buys
-
104
-
Number of sells
-
-75
-
Price
-
$24.00
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q3 2017
241 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2017.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 203 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 154M shares
.
Largest 10 shareholders include OppenheimerFunds, Inc. (24.8M shares), PRIMECAP MANAGEMENT CO/CA/ (23.1M shares), BlackRock Inc. (21M shares), VANGUARD GROUP INC (14.3M shares), Camber Capital Management LLC (5.2M shares), STATE STREET CORP (3.97M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (3.63M shares), Invesco Ltd. (3.61M shares), JANUS HENDERSON GROUP PLC (3.33M shares), and NORGES BANK (2.71M shares).
This table shows the top 203 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.